Alzheimer’s Drug Moves into Phase 1 Safety Study

Alzheimer’s Drug Moves into Phase 1 Safety Study
Tetra Discovery Partners, in collaboration with the NIH Blueprint Neurotherapeutics Network, announced the start of Phase 1 safety trials of BPN14770, a drug Tetra is developing as a potential treatment for neurological disorders such as Alzheimer’s disease (AD) and one that aims to both improve memory and slow disease progression. The NIH Blueprint Neurotherapeutics Network is a program designed to discover and develop

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *